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Background: Cystic Fibrosis (CF) is a monogenic disease with complex expression because of the action of genetic
and environmental factors. We investigated whether the ACE gene D/I polymorphism is associated with severity of CF.
Methods: A cross-sectional study was performed, from 2009 to 2011, at University of Campinas – UNICAMP. We
analyzed 180 patients for the most frequent mutations in the CFTR gene, presence of the ACE gene D/I polymorphism
and clinical characteristics of CF.
Results: There was an association of the D/D genotype with early initiation of clinical manifestations (OR: 1.519, CI:
1.074 to 2.146), bacterium Burkholderia cepacia colonization (OR: 3.309, CI: 1.476 to 6.256) and Bhalla score (BS)
(p = 0.015). The association was observed in subgroups of patients which were defined by their CFTR mutation
genotype (all patients; subgroup I: no mutation detected; subgroup II: one CFTR allele identified to mutation class I, II
or III; subgroup III: both CFTR alleles identified to mutation class I, II and/or III).
Conclusion: An association between the D allele in the ACE gene and the severity of CF was found in our study.
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CFTR gene mutations are crucial in modulating the se-
verity of cystic fibrosis (CF), along with environmental
factors and modifier genes [1-7]. CF occurs with hetero-
geneous clinical presentation. Among the clinical symp-
toms, that of highest variability is lung disease [5], and
modifier genes have been analyzed and associated as
possible factors that influence this clinical response [3,7].
The ACE gene codifies the Angiotensin Converting En-
zyme (ACE). Based on the pro-inflammatory property of
the ACE protein [8,9], the ACE gene was selected as a
possible genetic marker for clinical denotation in CF. The
ACE enzyme catalyzes the conversion of angiotensin I to
angiotensin II peptide, acting in the blood pressure con-
trol and the electrolyte balance of blood, being an import-
ant vasoconstrictor and stimulant of aldosterone [8,10].
The ACE gene is located on region 17q23.3 [11]. A
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reproduction in any medium, provided the or(deletion), with D allele characterized by a deletion of
the 287 pb DNA fragment in intron 16, affects the level
of the ACE enzyme. The polymorphism determines the
amount of ACE enzyme in the plasma and tissues
[8,10,12]. Individuals with I/I genotype have low concen-
trations of ACE; with D/D genotype, higher concentra-
tions; and with D/I genotype, intermediate.
The aim of this study was to investigate the association
of the ACE gene D/I polymorphism and CFTR genotype
with the severity of CF, determined by twenty four clin-
ical markers of the disease.Methods
We conducted a cross-sectional study with patients
from the CF Specialized Center at the University of
Campinas - UNICAMP, in a period from 2009 to 2011.
Diagnosis of CF was confirmed in patients through two
doses of sodium and chloride from the sweat with values
greater than 60 mEq/L. In a cohort of patients we identi-
fied two mutations in the CFTR gene. No patient had
received the neonatal screening test performed for CF.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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study. Thirty five patients without clinical data for statis-
tical analysis and those who did not sign the consent
form were excluded. Patients' DNA was obtained by
phenol-chloroform extraction. The concentration of
DNA used for analysis was 50 ng/mL, evaluated using
GE NanoVueTM Spectrophotometer (GE Healthcare
Biosciences, United States of America, Pittsburgh).
Determination of mutations in the CFTR gene
Determination of mutations in the CFTR gene was per-
formed in the Laboratory of Molecular Genetics for
mutations by polymerase chain reaction (F508del) and
restriction fragment length polymorphism method
(G542X, R1162X, R553X, G551D and N1303K). Some
mutations in patients with CF were obtained by sequen-
cing or MLPA (Multiplex Ligation-dependent Probe
Amplification) analysis: S4X, 2183A>G, 1717-G >A and
I618T. For sequencing and MLPA, we used the same
MegaBace1000W property (GE Healthcare Biosciences,
United States of America, Pittsburgh) [13]. The CFTR
genotype was used as a correction factor for statistical
analysis. All mutations identified were included in
classes one, two or three of the CFTR gene. Others iden-
tified mutations as class IV (P205S e R334W) were
included in the statistical analysis in the not identified
mutation subgroup, to minimize the associated factor
with the mutation classes in the CFTR gene, being that
the class IV is associated with a minor severity.
ACE gene D/I polymorphism analysis
ACE*D and ACE*I were identified by amplifying the re-
spective fragments from intron 16 of the ACE gene. The
PCR reaction contained 25μL with 100 ng of DNA,
1 μM of each primer, 200 μM of deoxynucleotide tri-
phosphate, 1.3 mM of MgCl2, 50 mM of KCl, 10 mM of
Tris–HCl (pH 8.4 at 25°C), 0.1% of Triton X-100 and
0.35U of Taq DNA polymerase. A pair of primers
(hace3s, 5'-GCC CTG CAG GTG TCT GCA GCATGT-
3'; hace3as, 5'-GGA TGG CTC TCC CCG CCT TG
TCTC-3') was used to amplify ACE*D and ACE*I, result-
ing in 319 bp and 597 bp, respectively [8,10,12,14]. The
procedure for thermal cycling consisted of initial de-
naturation at 94°C for 7 min, subsequent denaturation at
94°C for 30 min, annealing at 56°C for 45 min, and ex-
tension at 72°C for 2 min, repeated for 35 cycles fol-
lowed by a final extension at 72°C for 7 min. After the
addition of 5 μL of glycerol-based loading buffer, 7 μL of
the reaction was applied in agarose gel containing 1.5%
of acetate, 40 mM of TRIS, 2 mM of EDTA and 1 μg of
ethidium bromide per milliliter [8,10,12,14].
Due to the preferential amplification of the ACE*D in
heterozygous individuals, each initial sample with a D/D
genotype was passed through a second PCR reaction.Primers used: Hace 5a, 5'-TGG GAC CAC-AGC GCC
CGC CAC TAC-3' and hace 5c, 5'-TCG CCA GCC CTC
CCA TGC CCA TAA-3'. The PCR conditions were iden-
tical, except for the annealing temperature of 67°C. A
335 bp sequence was amplified in the presence of at
least one allele [8,10,12,14].
Clinical markers of severity of disease
Clinical scores of Kanga, Shwachman-Kulczycki and
Bhalla (BS) were performed blindly by three qualified
professionals from UNICAMP. These scores measure
the pulmonary exacerbation, severity of CF and struc-
tural impairment of the lung, respectively [15].
Nutritional status was obtained by calculating the Body
Mass Index (BMI) for age using the programs WHO
Anthro [16], for patients up to five years old, and WHO
Anthro Plus [17], for patients aged 5 to 19 years old. For
patients older than 19 years old, the BMI was calculated
[18]. Age of the diagnosis, the onset of pulmonary and
digestive symptoms, and the first isolation of Pseudo-
monas aeruginosa, were used as markers of initiation of
the disease. Results of cultures of sputum, performed
during routine diagnosis for the mucoid and non-
mucoid bacteria P. aeruginosa, Staphylococcus aureus,
Burkolderia cepacia (BC) and Achromobacter xylosoxi-
dans were included. Spirometry was performed in the
Laboratory of Pulmonary Physiology (LAFIP) according
the standards of the American Thoracic Society [19].
Parameters analyzed were: forced expiratory volume in
1 second (FEV1), forced vital capacity (FVC), FEV1/FVC
ratio, forced expiratory flow between 25-75% and trans-
cutaneous oxygen saturation (SaO2). For analysis of the
spirometry data, we used the predicted value in%.
Comorbidities (nasal polyposis, osteoporosis, diabetes
mellitus, pancreatic insufficiency and meconium ileus)
were also analyzed.
Statistical analysis
Variables described for the onset of illness (age at diag-
nosis, onset of pulmonary and digestive symptoms and
first isolation of P. aeruginosa) were categorized into
two groups according to the median of the data, due to
a non-normal distribution of data. Data categorized by
the median are divided into two cohorts with similar
sample size. For clinical evaluation of the scores from
the SaO2 and spirometry tests, analyses were performed
without adjusting the data. Bacteria isolated from the
culture of airway secretions were used as markers
according to the presence or absence of bacteria in three
consecutive cultures in the past two years. Comorbidities
were compared in terms of presence or absence. Statis-
tical analyses was performed using the Statistical Pack-
age for the Social Sciences (SPSS) v.17.0 [20] and the R
program version 2.12 (Comprehensive R Archive
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the problem of multiple testing [21], the level of signifi-
cance α, was adjusted using the Bonferroni correction
for four tests. Calculation of statistical power for the
sample, carried out by software GPOWER 3.0.5 [22],
showed a statistical power above 80% for the analysis
performed.
Data were compared by the linear and logistic regres-
sion analysis. For comparison between genotypes and
the variables with numerical distribution, T-student
test was applied to normal data distribution or Mann–
Whitney test to non-normal data distribution. Geno-
typed data for the CFTR gene was used to establish an
association between the CFTR gene, ACE gene and clin-
ical variables. All mutations analyzed in our study were
included in classes I, II or III. In the analyzed sample,
four different analyses were performed in order to detail
the effect of the genotype of the CFTR gene in clinical se-
verity. The analyses were performed in the cohorts: (1)
all patients with CF (180 patients); (2) patients with no
identified mutation in the CFTR gene (44 patients); (3)
patients with a mutant allele identified in the CFTR gene
belonging to class I, II or III mutation(51 patients); and
(4) patients with two mutations identified in the CFTR
gene belonging to class I, II and/or III (85 patients) -
main cohort to analyze the influence of modifier genes
associated with clinical variation in CF.
This study was approved by the Institutional Ethics
Committee from University of Campinas (Faculty of
Medical (No. 528/2008), and all patients signed a con-
sent form before beginning the study.
Results and discussion
From the sample of 180 analyzed patients, 90 (50%) were
male, 165 (91.7%) were European-Caucasian derived and
15 (8.3%) were African-derived individuals. The patients’
CFTR genotypes were: 44 patients (24.44%) without
identified mutation, 51 (28.33%) with one identified mu-
tation (25% F508del/-, 2.78% G542X/-, 0.56% R1162X/-)
and 85 (47.22%) patients with two identified mutations
(31.67% F508del/F508del, 6.67% F508del/G542X, 2.78%
F508del/R1162X, 2.22% F508del/N1303K, 0.56% F508del/
R553X, 0.56% F508del/S4X, 0.56% F508del/1717-1 G>A,Table 1 Description of quantitative variables (in months) of C
Variable N* Minimum Maximum
Age 179 7 288
Onset of the manifestation 170 0 156
Age at diagnosis 173 0 170
Onset of digestive symptons 150 0 150
Onset of lungs symptons 165 0 156
1st. P. aeruginosa 131 6 180
*N- number of patients.0.56% G542X/R1162X, 0.56% G542X/I618T, 0.56%
G542X/2183A >G and 0.56% R1162X/R1162X).
The spectrum of isolated Bacteria in secretion was: 76
(42.2%) with mucoid and 101 (56.1%) with non-mucoid
P. aeruginosa; 141 (78.3%), S. aureus; 25 (13.9%), B.
cepacia; and 18 (10%), A. xylosoxidans. Comorbidities
associated with CF severity were: 143 (79.4%) with pan-
creatic insufficiency; 33 (18.3%), nasal polyps; 33 (18.3%),
diabetes mellitus; 29 (16.1%), osteoporosis; and 27 (15%),
meconium ileus. For the variables with their numerical
distribution, see data listed in Table 1.
The ACE gene D/I polymorphism showed a higher fre-
quency for ACE*D (228/360 alleles) compared with
ACE*I (132/360 alleles). The genotype frequencies were:
72 (40.0%) with D/D; 84 (46.67%) with D/I; and 24
(13.3%) with I/I. The population is in Hardy-Weinberg
equilibrium (p > 0.05). Analysis of 70 healthy control
subjects in UNICAMP demonstrated the genotype fre-
quency: 20 (29%) with D/D, 37 (53%) of D/I, and 13
(18%) I/I [23]. There was no difference in frequency of
genotypes in relation to our study (p = 0.210). The ana-
lyses of the ACE gene D/I polymorphism with the clin-
ical variables are denoted in Table 2, where every
association possible between the clinical trial, CFTR mu-
tation identified and ACE gene D/I polymorphism can
be observed.
The ACE gene D/I polymorphism was associated with
the onset of clinical manifestations (Table 3), in the sub-
group of patients with one identified CFTR mutation.
We observed that patients with I/I genotype had OR:
0.297 (0.084 – 0.995), as protection factor, and the ones
with D/D genotype had OR: 1.519 (1.074 to 2.146), as a
severity factor.
The ACE*D is associated with a higher gene ex-
pression and, consequently, promotes a greater in-
flammatory response in the body, leading to early
symptoms [8,10,12,14,24]. The earliest onset of signs
and symptoms are accompanied by early onset of in-
flammation and deterioration of lung and pancreatic
functions. These symptoms are characteristic of severe
patients.
An association of the infection/colonization by B.
cepacia with ACE gene D/I polymorphism was identifiedF patients treated at the pediatric clinic at UNICAMP
Median Mean Standard error Standard deviation
154 212.64 14.13 189.04
3 34.69 8.33 108.54
24 91.47 12.44 163.60
3 40.69 8.93 109.32
6 42.88 9.24 118.68
31 102.60 15.16 173.47
Table 2 Association of ACE gene D/I polymorphism with variables used as markers of severity of CF, patients followed
at the pediatric center in UNICAMP distributed by CFTR gene mutation identified divided into cohorts








E p E p E p E p
Patients age W:0.791 0.374 W:3x10-5 0.995 W:2.969 0.085 W:0.001 0.984
Onset of clinical manifestations W:0.116 0.733 W:0.162 0.687 W:4.29 0.038 W:0.937 0.333
Diagnostic W:0.11 0.74 W:0.047 0.83 W:0.099 0.753 W:0.087 0.768
Onset of digestive symptons W:1.494 0.221 W:0.148 0.7 W:0.297 0.586 W:0.979 0.322
Onset of lung symptons W:0.021 0.885 W:0.039 0.843 W:0.401 0.526 W:1.302 0.31
BMI W:1.169 0.28 W:0.687 0.407 W:0.436 0.509 W:2.498 0.114
Nasal poliposys W:0.62 0.431 W:0.984 0.321 W:0.419 0.517 W:1.26 0.262
Diabetes W:0.358 0.55 W:0.016 0.901 W:0.174 0.676 W:0.184 0.668
Osteoporosis W:0.877 0.349 W:1.056 0.0304 W:0.561 0.454 W:0.083 0.773
Pancreatic insuficience W:1.6 0.206 W:0.693 0.406 W:1.063 0.302 W:0.182 0.669
Meconium ileus W-0.252 0.616 W:3.813 0.051 W:1.109 0.292 W:1.498 0.221
SaO2 F:2.131 0.142 F:0.022 0.884 F:1.868 0.178 F:1.344 0.25
Scores Bhalla F:6.526 0.012 F:0.2 0.689 F:4.942 0.032 F:4.013 0.049
Kanga F:1.3 0.256 F:0.486 0.492 F:0.027 0.871 F:3.765 0.057
SK F:2.361 0.127 F:0.286 0.597 F:1.042 0.312 F:1.243 0.269
FVC F:0.139 0.71 F:0.829 0.37 F:0.918 0.345 F:0.93 0.339
FEV1 F:0.785 0.377 F:0.622 0.436 F:0.907 0.348 F:2.797 0.099
FEV1/FVC F:0.891 0.347 F:0.005 0.943 F:2.212 0.146 F:0.156 0.694
FEF25-75% F:0.42 0.518 F:0.112 0.735 F:0.02 0.887 F:1.048 0.31
1a P. aeruginosa isolated W:0.962 0.327 W:0.702 0.402 W:0.16 0.69 W:0.099 0.753
Isolated Bacteria PAM W:0.92 0.338 W:0.141 0.708 W:2.016 0.156 W:0.165 0.684
PANM W:1.21 0.272 W:1.149 0.284 W:0.987 0.753 W:0.262 0.609
AX W:3.2 0.074 W:0.038 0.845 W:0.642 0.423 W:2.911 0.088
BC W:4.290 0.038 W:0.1 0.753 W:3.681 0.055 W:0.341 0.559
SA W:0.209 0.65 W:1.151 0.283 W:0.191 0.662 W:1.102 0.294
Analysis by linear regression (F) and logistic regression (W) test . Values below of 0.05 for p denote a clinical correlation between variables.
E - Statistical,% - percentage, SaO2 - transcutaneous oxygen saturation, FEV1 – forced expiratory volume in 1 second, FVC – forced expiratory capacity,
FEV1/FVC – ratio between two variables, forced FEF25-75, SC - expiratory flow at 25-75% of the pulmonary volume, SK - Shwachman-Kulczycki,
PAM – P. aeruginosa mucoid, PAM – P. aeruginosa non mucoid, AX – A. xylosoxidans, BC – B. cepacia, SA – S. aureus, BMI – body mass index, CF - cystic fibrosis,
ACE – angiotensin converting enzyme. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation
(51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II and/or III.
Others identified mutations as class IV (P205S e R334W) was included in the statistical analysis in the not identified mutation subgroup, to minimize the
associated factor with the mutation classes in the CFTR gene.
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count, OR: 4.509 (1.513 - 10.89), and for patients with
one CFTR mutation identified to class I, II or III, OR:
(1.43 - 40.38), for the D/D genotype (Table 4).
In the analysis of the BS and ACE gene D/I poly-
morphism, an association was found when no grouping
by CFTR genotype occurred (p = 0.015), as well in the
subgroup of patients for whom one class I, II and/or III
mutation have been identified (p = 0.038), and in the
subgroup of patients for whom two class I, II and/or III
mutation have been identified (p = 0.042) (Figure 1).
There was no difference between BS and the age
of patients after categorization. Younger patients
(≤ 154 months) had the same distribution of BS as
older patients (> 154 months) (p = 0.761). Age is not avariable that contributes to the association between the
ACE gene D/I polymorphism and BS. The analysis of an
association between the BS and the age of patients with
CF was performed in order to show that age had no in-
fluence on the score value analysis. We can conclude
that the ACE gene D/I polymorphism acts in genetic
modulation by association with BS. The BS is a com-
puted tomography score, which measures pulmonary in-
volvement, therapeutic effects and selection of patients
for transplantation, which detects anatomical changes of
the lung parenchyma [15,25]. The BS has low variation
between examiners, good reproducibility, high sensitiv-
ity and specificity, and high correlation with pulmonary
function test [15]. The values obtained in the score can
predict severity associated with deterioration of the
Table 3 Association of ACE gene D/I polymorphism with onset of clinical symptoms of patients in months considering
the cohorts to CFTR mutation
Groups ACE genotype ≤ 3 months > 3 months Total X2 p X2 p OR (CI 5-95%)
Without taking CFTR mutation
into account
I/I 38 28 66 0,880 0,644 0.012 0.9136 1.035 (0.555 - 1.931)
I/D 44 37 81 0.473 0.492 0.808 (0.4396 -1.484)
D/D 15 8 23 0.723 0.395 1.486 (0.5937, 3.721)
No identified CFTR mutation I/I 13 6 19 1,685 0,431 0.825 0.364 1.806 (0.5017 -6.498)
I/D 9 9 18 1.624 0.203 0.438 (0.122 - 1.576)
D/D 3 1 4 0.357 0.977 2.045 (0.194 - 21.58)
One CFTR mutation identified
class I, II or III
I/I 10 11 21 5,564 0,062 4.217 0.049 0.297 (0.084 – 0.995)
I/D 14 6 20 0.521 0.471 1.167 (0.775 – 1.757)
D/D 8 1 9 2.951 0.097 5,667 (0,647 – 49,61)
Two CFTR mutation identified
class I, II and/or III
I/I 15 11 26 0,599 1,026 0.773 0.379 1.527 (0.593 - 3.936)
I/D 21 22 43 0.122 0.727 0.854 (0.352 - 2.072)
D/D 4 6 10 0.511 0.704 0.611 (0.158 - 2.358)
Values below 0.05 for p denote clinical correlation between variables. OR - odds ratio, CI- confidence interval, ≤− less than or equal to, >− greater, D - deleted
allele, I - insertion allele. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) –
patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II or III.
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evolution can be observed by other variables such as
BMI and lung function.
Evolution of CF is secondary to mutation class in the
CFTR gene and environment factors. Many studies have
correlated mutations, polymorphisms and clinical vari-
ables to CF [5,26]. Association studies commonly face
the problem of having insufficient sample size for the
number of mutations in the CFTR gene to achieve a
homogeneous population and characterize the follow-up
of chronic and persistent lung disease [27].
Unlike other genetic diseases such as asthma, CF is
monogenic. It was expected that mutations in the CFTR
gene would determine the CF severity. Patients withTable 4 Association of the ACE gene D/I polymorphism, witho
(BC)
Group Ace genotype Presence Absence





No identified CFTR mutation I/I 3 18
I/D 2 16
D/D 1 3
One CFTR mutation identified




Two CFTR mutation identified




Values below 0.05 for p denote clinical correlation between variables. OR - odds rat
mutation (44 patients) – patients without of identified mutation in classes I, II or III.
class I, II, or III. Two identified mutation (85 patients) – patient with two mutations imutations of classes I, II and III have more severe clin-
ical forms than those with mutations IV, V and VI. How-
ever, we can observe changes in severity of CF in
patients with identical mutations in the CFTR gene [28].
Our study allowed us to characterize the association be-
tween the CFTR gene, the environment and one possible
CF modifier gene in patients of a Reference University
Center, using a statistical method of gene association
versus clinical markers.
The main environmental factor in the clinical variabil-
ity of CF is the patients´ access to treatment [28]. At our
center, treatment is guaranteed by the public health sys-
tem, which allows equal access for all patients included
in the study, and it is not an additional factor in theut CFTR genotype distribution and presence of B. cepacia
Total X2 p X2 p OR (CI 5-95%)
72 8.654 0.013 0.468 0.498 0.699 (0.319 – 1.534)
82 0.814 0.182 0.651 (0.304 – 1.394)
24 8,653 0.003 4.509 (1.513 – 10.89)
21 0.530 0.767 0.003 1.29 1.056 (0.188 - 5.925)
18 0.204 1.00 0.656 (0.107 - 4.041)
4 0.438 0.93 2.267 (0.196 - 26.27)
22 5.539 0.063 1.248 0.466 0.383 (0.069 - 2.117)
20 0.787 0.629 0.463 (0.084 - 2.562)
9 6.834 0.027 7.6 (1.43 - 40.38)
29 0.511 0.774 0.084 1.07 0.8077 (0.193 - 3.387)
45 0.039 1.10 0.875 (0.234 - 3.275)
11 0.495 0.764 1.833 (0.335 - 10.02)
io, CI- confidence interval, D - deleted allele, I - insertion allele. No identified
One identified mutation (51 patients) – patient with one identified mutation in
n class I, II or III.
Figure 1 Association of clinical data, with numerical distribution, with ACE gene D/I polymorphism and subgroups of CFTR mutations.
a Bloxplot denoting the association of the ACE gene D/I polymorphism in patients without taking CFTR gene into account. There were significant
differences between groups of patients with the genotypes D/D and I/I. # p: 0.092 * p: 0.768, ¥ p: 0.045. b. Bloxplot denoting the association of
the ACE gene D/I polymorphism in the subgroup of patients for whom one class I, II and III mutation have been identified. There were significant
differences between groups of patients with genotypes D/D and I/I. # p: 0.478, * p: 0.183; ¥ p: 0.043. c. Bloxplot denoting the association of the
ACE gene D/I polymorphism in the subgroup of patients for whom two class I, II and/or III mutation have been identified. There were significant
differences between groups of patients with genotype D/D and I/I. # p: 0.789 * p: 0.505; ¥ p: 0.05. Analysis was performed by Mann–Whitney test
considering a p-value of 0.05 as statistically significant.
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Brazil. Unlike the U.S. where the private system ensures
better treatment in CF [29], in Brazil, the public health
system is the reference.Some review articles have suggested a possible modu-
lation of the CF severity by the ACE gene. This fact is
based on the proinflammatory property of the ACE pro-
tein [2,3,30]. To the best of our knowledge, few studies
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the clinical CF severity [8,30,31]. Bartlett et al. (2009)
[31], in a multicenter study, studied the same poly-
morphism in relation to the propensity for liver disease
in patients with CF. They genotyped 124 patients with
CF and liver disease and 843 patients with CF and no
liver disease. In addition to this polymorphism, four
other genes, and their polymorphisms, were analyzed.
The polymorphism D/I in the ACE gene was not asso-
ciated with the presence of liver disease in CF patients,
OR: 1.11 (0.85 to 1.44).
Finally, the presence of B. cepacia complex increases
inflammation, favoring the exacerbation of immune re-
sponse, further deterioration of the bronchopulmonary
structure and causing rapid deterioration of lung func-
tion [32]. More studies to determine whether the pres-
ence of the D/D genotype causes increased gene
expression and, therefore, facilitates chronic infection by
different bacteria are needed. The D/D genotype of the
ACE gene D/I polymorphism was significantly associated
with higher values of BS. Higher values on the BS are
associated with greater clinical severity [15]. Patients
with the D/D genotype had higher severity, when com-
pared to patients with the I/I genotype. This data con-
firms that higher gene expression, given by the D allele,
leads to a change in the structure of the lung paren-
chyma, with subsequent increases in the value of the
score.
Our data suggest that ACE gene should be studied in
other populations, principally in populations with high
prevalence of chronic pulmonary infection by B. cepacia,
early onset of clinical manifestations and early onset of
severe lung disease (showed by BS).
Patient’s subgroups that were defined on the basis of
CFTR mutation analysis may also to be different in
comorbidities which may unmask the role of the ACE
gene as modifier that was studied in this study, being a
limitation of our work.Conclusion
CF patients with the D/D genotype for the ACE gene D/
I polymorphism have a higher risk for chronic infection
with BC and deterioration of lung function, character-
ized by a high BS. There was an association between the
presence of the D allele ACE gene and the severity of
CF. Further studies are needed to verify the pro-
inflammatory activity of this gene in CF, along with a lar-
ger CF population with homogeneous CFTR mutation;
suggesting that in this case, a multicenter study is
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